HUP0202757A3 - Heteropolycyclic compounds, pharmaceutical compositions containing them and their use as metabotropic glutamate receptor antagonists - Google Patents

Heteropolycyclic compounds, pharmaceutical compositions containing them and their use as metabotropic glutamate receptor antagonists

Info

Publication number
HUP0202757A3
HUP0202757A3 HU0202757A HUP0202757A HUP0202757A3 HU P0202757 A3 HUP0202757 A3 HU P0202757A3 HU 0202757 A HU0202757 A HU 0202757A HU P0202757 A HUP0202757 A HU P0202757A HU P0202757 A3 HUP0202757 A3 HU P0202757A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
compositions containing
receptor antagonists
glutamate receptor
metabotropic glutamate
Prior art date
Application number
HU0202757A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Nps Pharmaceuticals Inc Salt L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22530400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0202757(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nps Pharmaceuticals Inc Salt L filed Critical Nps Pharmaceuticals Inc Salt L
Publication of HUP0202757A2 publication Critical patent/HUP0202757A2/hu
Publication of HUP0202757A3 publication Critical patent/HUP0202757A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HU0202757A 1999-08-19 2000-08-18 Heteropolycyclic compounds, pharmaceutical compositions containing them and their use as metabotropic glutamate receptor antagonists HUP0202757A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14946499P 1999-08-19 1999-08-19
PCT/US2000/022618 WO2001012627A1 (en) 1999-08-19 2000-08-18 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Publications (2)

Publication Number Publication Date
HUP0202757A2 HUP0202757A2 (hu) 2002-12-28
HUP0202757A3 true HUP0202757A3 (en) 2006-03-28

Family

ID=22530400

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202757A HUP0202757A3 (en) 1999-08-19 2000-08-18 Heteropolycyclic compounds, pharmaceutical compositions containing them and their use as metabotropic glutamate receptor antagonists

Country Status (27)

Country Link
EP (1) EP1210344B1 (OSRAM)
JP (2) JP3790472B2 (OSRAM)
KR (1) KR100875222B1 (OSRAM)
CN (1) CN1313465C (OSRAM)
AT (1) ATE307129T1 (OSRAM)
AU (1) AU780191B2 (OSRAM)
BG (1) BG65586B1 (OSRAM)
BR (1) BR0013427A (OSRAM)
CA (1) CA2381975A1 (OSRAM)
CY (1) CY1105253T1 (OSRAM)
CZ (1) CZ2002599A3 (OSRAM)
DE (1) DE60023318T2 (OSRAM)
DK (1) DK1210344T3 (OSRAM)
EE (1) EE200200079A (OSRAM)
ES (1) ES2250177T3 (OSRAM)
HU (1) HUP0202757A3 (OSRAM)
IL (2) IL148157A0 (OSRAM)
IS (1) IS6275A (OSRAM)
MX (1) MXPA02001764A (OSRAM)
NO (1) NO322460B1 (OSRAM)
NZ (1) NZ517221A (OSRAM)
PL (1) PL353825A1 (OSRAM)
RU (1) RU2296127C9 (OSRAM)
SK (1) SK2512002A3 (OSRAM)
UA (1) UA75871C2 (OSRAM)
WO (1) WO2001012627A1 (OSRAM)
ZA (1) ZA200201358B (OSRAM)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IL157491A0 (en) * 2001-02-21 2004-03-28 Nps Pharmeceuticals Inc Heteropolycyclic compounds and pharmaceutical compositions containing the same
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
WO2002078745A2 (en) * 2001-04-02 2002-10-10 Brown University Research Foundation Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
WO2003051833A2 (en) * 2001-12-18 2003-06-26 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
DE60222698T2 (de) * 2001-12-18 2008-06-19 Merck & Co., Inc. Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
AU2002360621B2 (en) * 2001-12-19 2007-01-25 Merck & Co., Inc. heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
EP1485093B1 (en) * 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
SE0201943D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New use
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
NZ538339A (en) * 2002-08-09 2007-01-26 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
KR20050033070A (ko) 2002-08-09 2005-04-08 아스트라제네카 에이비이 메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸
CA2495179A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EP1613617A4 (en) * 2003-04-04 2009-02-18 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR-5 DIARYLSUBSTITUTED TRIAZOLE MODULATORS
WO2004103279A2 (en) * 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
EP1711491A1 (en) * 2003-12-24 2006-10-18 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
SI1716152T1 (sl) * 2004-02-18 2008-12-31 Astrazeneca Ab Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj
SG149900A1 (en) * 2004-02-18 2009-02-27 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
TW200538108A (en) 2004-02-19 2005-12-01 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2006004142A1 (ja) * 2004-06-30 2006-01-12 Banyu Pharmaceutical Co., Ltd. ビアリール誘導体
KR100621192B1 (ko) * 2004-10-13 2006-09-19 한국화학연구원 무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법
JP4557685B2 (ja) 2004-11-15 2010-10-06 独立行政法人理化学研究所 蛍光蛋白質
EP1844044B1 (en) 2005-01-14 2010-07-21 F.Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
US20090054491A1 (en) * 2005-06-28 2009-02-26 Astrazeneca Ab Use
KR101370280B1 (ko) 2005-07-26 2014-03-06 바이알 - 포르텔라 앤드 씨에이 에스에이 Ｃｏｍｔ 억제제로서의 니트로카테콜 유도체
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CN101291939B (zh) 2005-11-08 2013-02-13 弗·哈夫曼-拉罗切有限公司 作为mGluR5受体拮抗剂的噻唑并[4,5-C]吡啶衍生物
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
PT2003132E (pt) 2006-04-03 2014-05-26 Astellas Pharma Inc Derivados de oxadiazole como agonistas dos s1p1
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP2083921A2 (en) * 2006-09-04 2009-08-05 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
SI2069336T1 (sl) 2006-09-07 2013-03-29 Actelion Pharmaceuticals Ltd. Derivati piridin-4-ila kot imunomodulirna sredstva
CL2007002594A1 (es) 2006-09-08 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
KR20090051774A (ko) 2006-09-21 2009-05-22 액테리온 파마슈티칼 리미티드 페닐 유도체 및 면역조절제로서 이들의 용도
US8524746B2 (en) 2007-01-31 2013-09-03 Bial-Portela & Ca., S.A. Dosage regimen for COMT inhibitors
AU2008227979B2 (en) 2007-03-16 2014-02-06 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as S1P1 /EDG1 receptor agonists
MX2010001881A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de piridina como moduladores del receptor s1p1/edg1.
EP2215049B1 (en) 2007-10-31 2019-06-12 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
ES2449749T3 (es) 2007-11-01 2014-03-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirimidina
ATE548355T1 (de) * 2007-12-20 2012-03-15 Bayer Pharma AG 4- (4-cyano-2-thioaryl) -dihydropyrimidinone und ihre verwendung
WO2009100438A2 (en) * 2008-02-07 2009-08-13 Massachusetts Eye & Ear Infirmary Compounds that enhance atoh-1 expression
RU2010140847A (ru) 2008-03-07 2012-04-20 Актелион Фармасьютиклз Лтд (Ch) Новые производные аминометилбензола
RU2010139315A (ru) 2008-03-17 2012-04-27 Биал - Портела Энд Ка., С.А. (Pt) Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола
JP5592388B2 (ja) 2008-10-31 2014-09-17 メルク・シャープ・アンド・ドーム・コーポレーション 疼痛治療用のｐ２ｘ３受容体アンタゴニスト技術分野
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
WO2010111058A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
CA2755768A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
US8946231B2 (en) 2009-03-23 2015-02-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
MX340360B (es) 2009-04-01 2016-07-07 Bial-Portela & Ca S A Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
CN102459203A (zh) * 2009-04-13 2012-05-16 Irm责任有限公司 用于调控视磺醇与视黄醇结合蛋白4(rbp4)结合的组合物和方法
MY153617A (en) 2009-07-16 2015-02-27 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
MX350009B (es) 2011-01-19 2017-08-23 Idorsia Pharmaceuticals Ltd Derivados de 2-metoxi-piridin-4-ilo.
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
JP6456143B2 (ja) 2011-12-13 2019-01-23 ノヴィファーマ，エス．アー． カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
JP5946288B2 (ja) * 2012-02-24 2016-07-06 公立大学法人名古屋市立大学 新規ヒドロキサム酸誘導体及びその用途
WO2014127195A1 (en) 2013-02-15 2014-08-21 Monsanto Technology Llc 3,5-disubstituted-4,5-dihydro-1,2,4-oxadiazoles for controlling nematode pests
EP2853532B1 (en) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
ES2770348T3 (es) 2015-05-20 2020-07-01 Idorsia Pharmaceuticals Ltd Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
ES2820839T3 (es) 2015-06-23 2021-04-22 Kissei Pharmaceutical Derivado de pirazol, o sal farmacéuticamente aceptable del mismo
CA3018375A1 (en) * 2016-03-30 2017-10-05 Carin Sjolund Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages
IL298250B2 (en) * 2018-04-12 2025-01-01 Bayer Ag N-(cyclopropylmethyl)-5-(methylsulfonyl)-N-{1-[1-(pyrimidin-2-yl)-H1-1, 2, 4-triazol-5-yl]ethyl}benzamide derivatives and pyridine-carboxamide derivatives are compatible as pesticides
KR102276327B1 (ko) * 2019-06-25 2021-07-12 연세대학교 산학협력단 신규 옥사다이아졸 화합물 및 이를 포함하는 당뇨 예방 또는 치료용 조성물
WO2021046183A1 (en) * 2019-09-05 2021-03-11 Trevena, Inc. Methods of treating epilepsy using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1149011B (de) * 1960-04-05 1963-05-22 Hoechst Ag Verfahren zur Herstellung von 3, 5-disubstituierten 1, 2, 4-Oxdiazolen
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
US4003909A (en) * 1974-07-22 1977-01-18 E. R. Squibb & Sons, Inc. [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
KR100297445B1 (ko) * 1995-04-21 2001-10-25 페더 벨링 벤즈이미다졸화합물및감마-아미노부틸산수용체복합체의조절인자로서의그들의용도
AU6526896A (en) * 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
AU771358B2 (en) * 1997-11-21 2004-03-18 Astrazeneca Ab Metabotropic glutamate receptor antagonists for treating central nervous system diseases

Also Published As

Publication number Publication date
NO20020823D0 (no) 2002-02-19
UA75871C2 (en) 2006-06-15
CN1379775A (zh) 2002-11-13
EE200200079A (et) 2003-06-16
KR20020038731A (ko) 2002-05-23
KR100875222B1 (ko) 2008-12-19
IL148157A0 (en) 2002-09-12
AU6782400A (en) 2001-03-13
AU780191B2 (en) 2005-03-03
CY1105253T1 (el) 2010-03-03
SK2512002A3 (en) 2002-07-02
CA2381975A1 (en) 2001-02-22
CN1313465C (zh) 2007-05-02
MXPA02001764A (es) 2004-03-19
EP1210344A1 (en) 2002-06-05
BR0013427A (pt) 2002-07-30
ES2250177T3 (es) 2006-04-16
JP3790472B2 (ja) 2006-06-28
NO20020823L (no) 2002-04-17
NZ517221A (en) 2004-01-30
WO2001012627A1 (en) 2001-02-22
ATE307129T1 (de) 2005-11-15
JP2006143746A (ja) 2006-06-08
HUP0202757A2 (hu) 2002-12-28
EP1210344B1 (en) 2005-10-19
NO322460B1 (no) 2006-10-09
BG106493A (en) 2003-01-31
DE60023318T2 (de) 2006-07-20
RU2296127C9 (ru) 2007-08-27
ZA200201358B (en) 2003-07-30
IS6275A (is) 2002-02-18
PL353825A1 (en) 2003-12-01
RU2296127C2 (ru) 2007-03-27
DE60023318D1 (de) 2006-03-02
JP2003507378A (ja) 2003-02-25
DK1210344T3 (da) 2006-03-06
IL148157A (en) 2007-07-04
CZ2002599A3 (cs) 2002-06-12
BG65586B1 (bg) 2009-01-30
HK1047929A1 (en) 2003-03-14

Similar Documents

Publication Publication Date Title
HUP0202757A3 (en) Heteropolycyclic compounds, pharmaceutical compositions containing them and their use as metabotropic glutamate receptor antagonists
HUP9901245A3 (en) Indole derivatives useful as endothelin receptor antagonists, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP0301654A3 (en) Novel n-pyrimidinyl-sulfamides, their use as endothelin receptor antagonists and pharmaceutical compositions containing them
PL357433A1 (en) Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
PL357418A1 (en) Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
HUP0200992A3 (en) Indoline derivatives as progesterone antagonists and pharmaceutical compositions containing them and their use
HUP0303081A3 (en) Thrombin receptor antagonists, pharmaceutical compositions containing them and their use
HUP0500107A3 (en) 1-alkyl-1-azoniabicyclo[2.2.2.]octane carbamate derivatives, pharmaceutical compositions comprising thereof and their use as muscarinic receptor antagonists
HUP0203528A3 (en) Piperidine derivatives useful as ccr5 antagonists, pharmaceutical compositions containing them and their use
HUP0200714A3 (en) Pharmaceutical compounds, pharmaceutical compositions containing them and their use
HUP0200803A3 (en) Substituted bicyclic heteroaryl compounds as integrin antagonists, pharmaceutical compositions containing them and the intermediates
PL350428A1 (en) 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
HUP0203836A3 (en) 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use
HUP0200996A3 (en) Amine derivatives, pharmaceutical compositions containing them and their use
HUP0302327A3 (en) Ecteinascidin derivatives their use, pharmaceutical compositions containing them
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
AU2002352476A1 (en) Urea derivatives and their use as vanilloid receptor antagonists
HUP0203722A3 (en) Substituted phenyl-piperazine derivatives, pharmaceutical compositions containing them and their use
HUP0300599A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use
HUP0200707A3 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists pharmaceutical compositions containing them and their use
HUP0203332A3 (en) Cyclothiocarbamate derivatives, their use as progesterone receptor modulators and pharmaceutical compositions containing them
HUP0204113A3 (en) Novel integrin receptor antagonists, pharmaceutical compositions containing them and their use
PL350536A1 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor
IL144299A0 (en) N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
HUP0200080A3 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists and pharmaceutical compositions containing the compounds

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ASTRAZENECA AB, SE

Free format text: FORMER OWNER(S): NPS PHARMACEUTICALS, INC., US

FD9A Lapse of provisional protection due to non-payment of fees